Start Time: 16:30 January 1, 0000 2:24 PM ET
Inari Medical, Inc. (NASDAQ:NARI)
Q2 2024 Earnings Conference Call
July 30, 2024, 16:30 PM ET
Company Participants
Drew Hykes - President and CEO
Mitch Hill - CFO
Tom Tu - Chief Medical Officer
Kevin Strange - SVP of Finance, Accounting, Strategy and Business Development
Marissa Bych - Gilmartin Group LLC
Conference Call Participants
Kallum Titchmarsh - Morgan Stanley
Stephanie Pezzi - Bank of America
Marie Thibault - BTIG
Bill Plovanic - Canaccord
Chris Pasquale - Nephron Research
Adam Maeder - Piper Sandler
Richard Newitter - Truist
Margaret Kaczor - William Blair
Operator
Good afternoon, everyone, and welcome to the Inari Medical, Inc. Second Quarter 2024 Earnings Conference Call. All participants are in a listen-only mode. At the end of the company's prepared remarks, we will conduct a question-and-answer session. As a reminder, this call is being recorded and will be available on the company's website for replay shortly.
I would now like to turn the floor over to Marissa Bych. Ma'am, please go ahead.
Marissa Bych
Thank you, operator. Welcome to Inari's conference call to discuss our second quarter 2024 financial performance. Joining me on today's call are Drew Hykes, President and Chief Executive Officer; and Mitch Hill, Chief Financial Officer.
This call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements made on this call do not relate to matters of historical fact should be considered forward-looking statements, including statements related to Inari's estimated full year 2024 revenue, operating loss or profitability expectations and the expected operating performance and potential strategic benefits of LimFlow. These statements are based on Inari's current expectations, forecasts and assumptions, which are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Actual outcomes and results could differ materially from any results, performance or achievements expressed or implied by the forward-looking statements due to several factors. Please review Inari's most recent filings with the SEC particularly the risk factors described in our latest Form 10-K for additional information. Any forward-looking statements provided during this call, including projections for future performance, are based on management expectations as of today. Inari undertakes no obligation to update these statements, except as required by applicable law.
On today's call, we will refer to both GAAP and non-GAAP financial measures in announcing our Q2 2024 results. Please refer to today's press release for a reconciliation of the non-GAAP measure discussed on this call and referred to in that release. The press releases and slides accompanying this call are available on our website at anarimedical.com. A recording of today's call will be available on our website by 5 PM Pacific Time today.